Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Ketoconazole Esteve (previously Ketoconazole HRA)

Ketoconazole Esteve 200 mg tablets · Abschnitt 4.5 · PDF-Seite 12–13

HOS-132868 · Präparat HOS-097310

12 Medicinal product by Expected effect on drug levels Recommendation for co- therapeutic area administration Beta Blockers Nadolol ↑in plasma concentrations of nadolol Careful monitoring. Dose adjustment have been observed of nadolol may be required. Calcium Channel Blockers Felodipine AUC: ↑ has been observed Contraindicated due to an increase Nisoldipine Cmax: ↑ has been observed risk of edema and congestive heart failure (see section 4.3). Other dihydropyridines Potential ↑in plasma concentrations of Careful monitoring. Dose adjustment Verapamil these drugs of dihydropyridines and verapamil may be required. Cardiovascular Drugs, Miscellaneous Ranolazine Ranolazine: Contraindicated due to the potential AUC: ↑ 3.0 to 3.9-fold for serious cardiovascular events including QT prolongation (see section 4.3). Bosentan Bosentan: Not recommended due to the AUC: ↑ 2-fold potential for hepatic toxicity (see Cmax: ↑ 2-fold section 4.3). Aliskiren Aliskiren: Careful monitoring. AUC: ↑ 1.8-fold Dose adjustment of aliskiren may be required. Diuretics Eplerenone Eplerenone: Contraindicated due to the increased AUC: ↑ 5.5-fold risk of hyperkalaemia and hypotension (see section 4.3). Gastrointestinal Drugs Aprepitant Aprepitant: Careful monitoring. AUC: ↑ 5-fold Dose adjustment of aprepitant may be required Domperidone Domperidone: Not recommended due to an AUC: ↑ 3.0 fold increased risk in QT prolongation. Cmax: ↑ 3.0 fold Naloxegol Naloxegol Not recommended AUC ↑ 12.9 fold Cmax ↑ 9.6 fold Immunosuppressants Everolimus Everolimus: Contraindicated due to the large Sirolimus (rapamycin) AUC: ↑ 15.3-fold increase in these medicinal products Cmax: ↑ 4.1-fold concentrations (see section 4.3). Sirolimus (rapamycin): AUC: ↑ 10.9-fold Cmax: ↑ 4.4-fold Temsirolimus Temsirolimus: Not recommended unless necessary. AUC: ↔ Careful monitoring and dose Cmax: ↔ adjustment of these medicinal Tacrolimus Ciclesonide active metabolite: products may be required. Ciclosporine AUC: ↑ 3.5-fold Budesonide Ciclesonide Rest of drugs ↑in plasma concentrations of these drugs have been observed

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): temsirolimus (HOS-117078) eplerenone (HOS-089050) felodipine (HOS-108908) aprepitant (HOS-112506) ciclesonide (HOS-132871) aliskiren (HOS-086927) domperidone (HOS-114656) nadolol (HOS-132869) calcium (HOS-085615) naloxegol (HOS-109428) budesonide (HOS-086332) tacrolimus (HOS-085202) nisoldipine (HOS-114251) everolimus (HOS-086310) sirolimus (HOS-085172) bosentan (HOS-086291) ranolazine (HOS-086141) verapamil (HOS-090602)